Tags : preclinical

Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline to

Shots: Shots: Boehringer Ingelheim acquires two preclinical programs from Northern Biologic to foster its cancer immunology portfolio in exchange Northern will receive upfront, milestones and other consideration payments. The acquisition will support Boehringer’s strategy to target ‘’cold tumors with synergistic combination approaches” The first program is an Ab inhibitor of Periostin, which contributes to cancer […]Read More